Takeda unit urges Fed Circ to revive antibody patent

14-06-2022

Takeda unit urges Fed Circ to revive antibody patent

Michael Vi / Shutterstock.com

Baxalta, a subsidiary of Japan-headquartered pharmaceutical company Takeda, has asked the US Court of Appeals for the Federal Circuit to overturn a decision that invalidated its antibody patent.


Genentech, Baxalta, Hemlibra, haemophilia, Takada, antibodies, patent infringement

LSIPR